An interventional study of ACT-based nursing intervention in Ovarian Neoplasm ; Psychological Distress, sponsored by Yonsei University. Not yet recruiting. Open to female participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Yonsei University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ovarian Neoplasms by Yonsei University — 4 open to participants now, 6 under way, none of them phase 3. Ovarian Neoplasms · Yonsei University.
Among the 14 studies in Ovarian Neoplasms by Yonsei University, this one is the only one that started in 2025, is one of 2 with no phase, and was the 12th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →4 of the 14 studies in Ovarian Neoplasms by Yonsei University are open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 18+ · Women only
Yonsei University · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
Ages 19–85 · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 19 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 44 across the 9 interventional studies, 100 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
2 of the studies in Ovarian Neoplasms by Yonsei University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340164Yonsei UniversityTrastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy | 2026-12-30 |
| NCT06023862Yonsei UniversityA Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Ovarian Neoplasms by Yonsei University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the feasiblity and effectiveness of an Acceptance and Commitment Therapy (ACT)-based nursing intervention aimed at managing psychological flexibility, distress, anxiety, depression, fear of cancer recurrence/progression, quality of life, and symptoms. Patients will participate in a single online session with a nurse, followed by a daily self-monitoring survey online for one week. Data will be collected at baseline (prior to the ACT session), on day 8 (after one week of self-monitoring), and at 5 weeks. Primary outcome is psychological flexibility.
This study is a preliminary single-group pre-post design aimed at developing and evaluating the feasibility of an ACT-based nursing intervention for distress management in patients with ovarian cancer. A total of 25 ovarian cancer patients who consent to participate will be enrolled in the study. Paticipants will receive a one-time ACT-based nursing intervention lasting approximately 60 minutes.
The researcher will coordinate schedules with participants to deliver the ACT-based nursing intervention using Zoom, a video conferencing platform which minimizes time and location constraints. Before the intervention, the research will ensure that the participants' video conferencing is working properly to minimize potential difficulties during the session.
Following the single-session intervention, the researcher will send a daily Google Form link to participants for seven consecutive days. Participants will be encouraged to access the link and complete self-monitoring surveys to reinforce the key components addressed in the program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental group with application of ACT-based nursing intervention
Other: ACT-based nursing intervention
ACT-based nursing intervention is a 1:1 single online session with a nurse, which takes about 60 minutes followed by a daily self-monitoring survey for one week, which encourages patients to practice ACT.
Change from baseline psychological distress on the last day of self-monitoring (Day 8)
Psychological distress measured by Distress Thermometer.
Time frame: Psychological distress will be assessed at baseline and on the last day of self-monitoring (Day 8).
Change from baseline depression
depression measured by the Hospital Anxiety and Depression Scale (HADS).
Time frame: within 3 weeks after the last day of self-monitoring (window: 7 days)
Change from anxiety
Anxiety by the Hospital Anxiety and Depression Scale (HADS).
Time frame: within 3 weeks after the last day of self-monitoring (window: 7 days)
Change from fear of cancer recurrence
Fear of cancer recurrence measured by the Fear of Cancer Recurrence Index (FCRI).
Time frame: within 3 weeks after the last day of self-monitoring (window: 7 days)
Change from psychological flexibility
Psychological flexibility measured by the Acceptance and Action Questionnaire-II (AAQ-II).
Time frame: within 3 weeks after the last day of self-monitoring (window: 7 days)
Change from quality of life
Quality of life measured by the ECORTC QLQ C-30.
Time frame: within 3 weeks after the last day of self-monitoring (window: 7 days)
Change from symptoms
Symptoms measured by the EORTC QLQ-OV28.
Time frame: within 3 weeks after the last day of self-monitoring (window: 7 days)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for Jun 2025, 4 months later.
Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 4 months is below that.
Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.